The Alzheimer’s treatment landscape is rapidly changing following recent regulatory approvals for disease-modifying therapies. These advances have created an urgent need for accurate patient screening, spurring rapid growth in the global Alzheimer’s diagnostics market. Valued at about $3.5 billion in 2023, the market is expected to reach $8 billion by 2030, reflecting strong, sustained demand for diagnostic tools.
This growth is closely tied to the requirements of new anti‑amyloid therapies. Patients must first be confirmed to have amyloid‑beta pathology before treatment can begin, making diagnostics a critical gatekeeper. Additionally, therapy guidelines recommend continued monitoring to determine when treatment should be paused or stopped, creating ongoing demand for diagnostic testing throughout a patient’s care journey.
Among these tools, Positron Emission Tomography (PET) imaging remains the gold standard for visualizing amyloid plaques. The U.S. market for Alzheimer’s PET is projected to reach $1.5 billion by 2030. Driving this growth are increased uptake of amyloid-targeted therapies, which necessitates the use of PET imaging agents for patient selection, and favorable reimbursement and coverage policies. These two dynamics have strengthened the foundation for sustained market growth.
At the same time, blood-based biomarker tests are emerging as cost-effective screening tools. These tests measure markers like p-tau217 and help rule out patients unlikely to have Alzheimer’s pathology, narrowing the pool for more expensive PET scans. Together, these diagnostic workflows create a harmonious system that ensures consistent demand across both advanced and accessible testing modalities.
The Alzheimer’s diagnostics market’s rapid growth tells a compelling story of innovation and integration. The seamless integration of diagnostics and therapeutics ensures a sustained market for technologies spanning screening, staging, and monitoring. For investors, this presents a rare opportunity to capitalize on the radiopharmaceutical sector’s rapid expansion. We believe companies developing advanced PET tracers are particularly well-positioned to thrive. By staying attuned to clinical advancements and regulatory developments, investors can confidently navigate the evolving landscape and secure long-term value.
For more information on related investment opportunities and insights, read Illuminating the Road Less Traveled in Biotech: Radiopharmaceuticals—Fourth Edition, published on January 8, 2026, by William Blair biotech research analyst Andy Hsieh, Ph.D.